Roche AG, of Basel, Switzerland, said the subcutaneous formulation of Roactemra (tocilizumab) received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) to treat moderate to severe active rheumatoid arthritis (RA) in patients who responded inadequately to or could not tolerate therapy with one or more disease-modifying antirheumatic drugs or tumor necrosis factor inhibitors.